Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Dr. Karl Thomae Gmbh

Boehringer Ingelheim Pharma Kg

Karl Thomae Gmbh

Vitae Pharmaceuticals, Inc.

Other

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Kg

Boehringer Ingelheim International Pharma Gmbh & Co. Kg

Vitae Pharmaceuticals, Inc./boehringer-ingelheim

Boehringer Ingelheim Vetmedica Gmbh

Neurocrine Biosciences, Inc.

Frank Himmelsbach

Matthias Eckhardt

Elke Langkopf

Leo Thomas

Birgit Jung

Johannes M Weisenberger

Helmut Pieper

Mohammad Tadayyon

Volkhard Austel

Michael Mark

Flavio Solca

Peter Eickelmann

Roland Maier

Guenter Linz

Thomas Mueller

Brian Guth

Stefan Peters

Wolfgang Eisert

Ralf Lotz

Stefan Matthias Blech

Gunter Linz

Linghang Zhuang

Edward Leon Barsoumian

Norbert Hauel

Armin Heckel

Georg Dahmann

Bernd Nosse

Holger Wagner

Iris Kauffmann-Hefner

Klaus Dugi

Bradford S Hamilton

Ralf R H Lotz

Thomas Metz

Katerina Leftheris

Suresh B Singh

Colin M Tice

Yuanjie Ye

Neil Ashweek

Anke Baum

Thomas Muller

Xiao-Jun Wang

Nicole Harriott

Zhenrong Xu

Achim Sauer

Walter Spevak

Andreas Blum

Hans-Juergen Martin

Li Feng Zhang

David A Claremon

Joerg Kley

Herbert Nar

Alexander Pautsch

Martin Steegmaier

Steffen Steurer

Rolf Goeggel

Dhileepkumar Krishnamurthy

Andreas Schoop

Zhengxu Han

Norbert Redemann

Martin Lenter

Wenjun Tang

Martin Schuehle

Kurt Schromm

Ernst-Otto Renth

Ralf Anderskewitz

Annette Schuler-Metz

Thorsten Lehmann-Lintz

Wolfgang Grell

Beat Theodor Weber

Rainer Walter

Franz Birke

Armin Fugner

Anthony S Prokopowicz

Gisela Schnapp

Bing-Shiou Yang

Chris H Senanayake

Chris Hugh Senanayake

Wolfgang Eberlein

Hans Briem

Wei Zhao

Gerald Juergen Roth

Niklas Heine

Dieter Wolfgang Hamprecht

Sara Frattini

Salvacion Cacatian

Wesley Peter Blackaby

Dieter Wiedenmayer

Ian Linney

Steffen Breitfelder

Cornelia Dorner-Ciossek

Klaus Fuchs

Klaus Klinder

Iain Lingard

Markus Ostermeier

Rainer Soyka

Bernd Wellenzohn

Ulrike Tontsch-Grunt

Jacobus C Van Meel

Remko Alexander Bakker

Matthias Austen

The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

Uses of DPP IV inhibitors

Intermediate compounds are described herein and which are used to manufacture a crystalline compound 1-cyano-2-(4-cyclopropyl-benzyl)-4-(&#x3b2;-D-glucopyranos-1-yl)-benzene L-proline monohydrate.

Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(&#xdf;-d-glucopyranos-1-yl)-benzene, L-proline and water

The invention relates to a process for the manufacture of the crystalline compound according to formula (I) comprising the steps (a) deacetylating the final intermediate (FI), (b) forming the crystalline compound according to formula (I) by reacting the deacetylated final intermediate of step (a) with L-proline and water and isolating the final reaction product; processes of manufacturing intermediates thereof; process intermediates and their uses in the processes according to the present invention.

Synthesis of 1:1:1 co-crystal of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(&#x3b2;-D-glucopyranos-1-yl)-benzene, L-proline and water

The invention relates to new heteroaryl derivatives of the formula wherein X is selected from the group consisting of: N and CH; X is selected from the group consisting of: N and CF; (with the proviso that at least one of Xand Xis N), and A is as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors

The present invention relates to processes for preparing the compounds of general formula I, wherein the groups Rand Rare defined according to claim. Furthermore this inventions relates to intermediates obtained in these processes.

Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein

The invention relates to new benzonitrile derivatives of the formula (I) wherein Rto Rand A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them. 

4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors

The present invention relates to substituted xanthines of general formula wherein Rto Rare as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

The present invention relates to compounds of general formula (I), wherein R, R, R, A, A, m and n are defined as in claim, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. 

Azabenzimidazole derivatives

Compounds of formula I wherein R, L, n, HetAr, and HetArare as defined herein, and salts thereof, pharmaceutical compositions containing these compounds, and methods for treating diseases or conditions which are mediated by activating the G-protein-coupled receptor GPR119, such as diabetes, dislipidemia, or obesity, by administering to a patient in need thereof these compounds or a pharmaceutically acceptable salt thereof.

N-cyclopropyl-N-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof

The present invention relates to compounds defined by formula I wherein the variables R, R, R, R, and m are defined as in claim, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11&#x3b2;-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.

Aryl- and heteroarylcarbonyl derivatives of hexahydroindenopyridine and octahydrobenzoquinoline

8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions

The present invention relates to compounds of general formula I, wherein the group R, R, X and Y are defined as in claim, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

Growing community of inventors

Mittelbiberach, Germany

Frank Himmelsbach